J. Goldman & CO LP Crispr Therapeutics Ag Call Options Transaction History
J. Goldman & CO LP
- $3.75 Billion
- Q2 2025
Call Options
1 transactions
Others Institutions Holding CRSP
# of Institutions
542Shares Held
68.5MCall Options Held
3.67MPut Options Held
2.25M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$574 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA5.59MShares$316 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.68MShares$208 Million0.11% of portfolio
-
State Street Corp Boston, MA3.27MShares$184 Million0.01% of portfolio
-
Ubs Group Ag2.84MShares$160 Million0.02% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.4B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....